EPO to grant UC, Berkeley CRISPR patent
Natali_Mis / iStockphoto.com
Biopharmaceutical company Sarepta Therapeutics is exploring the potential of CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy (DMD).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Sarepta, CRISPR, Duchenne muscular dystrophy, licence, Duke University, CRISPR Cas9, gene editing